The Ascent to Pharmaceutical Leadership Eli Lilly’s journey to the top has been nothing short of meteoric. In 2020, the…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
Eli Lilly, a pharmaceutical giant that just last year occupied the ninth position, has ascended to the pinnacle of the…
Read More
Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery
Researchers in China have achieved a significant breakthrough in ophthalmic pharmacology, developing innovative eye drops derived from pig semen that…
Read More
Eli Lilly Ascends to Pharmaceutical Revenue Pinnacle Amidst Oral GLP-1 Approval, Yet Wall Street Remains Measured
Indianapolis-based pharmaceutical giant Eli Lilly and Company has achieved a remarkable milestone, surpassing all global pharmaceutical competitors to claim the…
Read More
MEDVi Under Scrutiny Following FDA Warning, Deceptive AI Advertising, and Multiple Lawsuits
In 2024, OpenAI CEO Sam Altman famously predicted that a single entrepreneur, leveraging the transformative power of artificial intelligence, could…
Read More
Pharma 50: Keytruda Holds Top Brand Slot, But Tirzepatide and Semaglutide Have Already Passed It at the Molecule Level in FY2025
Merck’s Keytruda (pembrolizumab) maintained its formidable position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording an impressive…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The fiscal year 2025 witnessed a dramatic recalibration at the apex of the pharmaceutical industry’s sales leaderboard, characterized by a…
Read More
Medvi’s QUAD Erectile Dysfunction Cocktail Raises Significant Safety Concerns Amidst Regulatory Scrutiny and Questionable Marketing Practices
The burgeoning telehealth industry, lauded for its potential to democratize healthcare access, is facing intensified scrutiny as companies push the…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read More
How Medvi Built a $1.8 Billion Telehealth Empire in Regulatory Blind Spots: A Deep Dive into AI, Compounding, and Fragmented Oversight
The rapid ascent of Medvi, a telehealth company projected to achieve a staggering $1.8 billion valuation this year, has thrust…
Read More
